Contemporary Accounts in Drug Discovery and Development. Группа авторов

      41 41 Dubin, R.F. and Shah, S.J. (2016). Curr. Heart Fail. Rep. 13: 132–139.

      42 42 Boettcher, M., Thomas, D., Mueck, W. et al. (2021). Eur. J. Clin. Pharmacol. 77 (4): 527–537. https://doi.org/10.1007/s00228‐020‐03023‐7.

      43 43 Boettcher, M., Loewen, S., Gerrits, M., and Becker, C. (2021). Clin. Pharmacokinet. 60 (3): 337–351. https://doi.org/10.1007/s40262‐020‐00935‐6.

      44 44 FDA (2021). VERQUVO. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214377s000lbl.pdf (accessed 26 September 2021).

      45 45 Boettcher, M., Gerisch, M., Lobmeyer, M. et al. (2020). Clin. Pharmacokinet. 59 (11): 1407–1418. https://doi.org/10.1007/s40262‐020‐00895‐x.

      46 46 Meyer, M., Schneckener, S., Loosen, R. et al. (2021). Leveraging translational approaches for clinical development of vericiguat. Poster presented at the European Society of Cardiology Congress 2021, The Digital Experience (27–30 August 2021).

      47 47 Pieske, B., Butler, J., Filippatos, G. et al. (2014). Eur. J. Heart Fail. 16: 1026–1038.

      48 48 Voors, A.A. and van Veldhuisen, D.J. (2012). Eur. J. Heart Fail. 14: 955–956.

      49 49 Butler, J., Braunwald, E., and Gheorghiade, M. (2014). JAMA 312: 789–790.

      50 50 Gheorghiade, M., Greene, S.J., Butler, J. et al. (2015). JAMA 314: 2251–2262.

      51 51 Pieske, B., Patel, M.J., Westerhout, C.M. et al. (2019). Eur. J. Heart Fail. 21: 1596–1604.

      52 52 Pieske, B., Maggioni, A.P., Lam, C.S.P. et al. (2017). Eur. Heart J. 38: 1119–1127.

      53 53 Filippatos, G., Maggioni, A.P., Lam, C.S.P. et al. (2017). Eur. J. Heart Fail. 19: 782–791.

      54 54 Butler, J., Lam, C.S.P., Anstrom, K.J. et al. (2019). Circ. Heart Fail.: 12, e005998.

      55 55 Armstrong, P.W., Lam, C.S.P., Anstrom, K.J. et al. (2020). JAMA 324: 1512–1521.